NeoGenomics is trading 5.77% down now at $16.00 after no clear company-specific catalyst was identified for August 24, 2026.

  • Recent company updates include strong second-quarter results and raised full-year guidance; available analyst sentiment remains broadly positive.
  • Broader markets are modestly lower, but the decline does not clearly explain NeoGenomics’ larger pre-market move.